MICHAEL FITZHUGH
The Burrill Report
AbbVie and InterMune are suing the European Medicines Agency to block it from releasing clinical trial data requested by competitors in freedom of information requests submitted to the regulator.
The lawsuits, first reported in the Financial Times, seek injunctions to prevent the release of detailed information about AbbVie’s rheumatoid arthritis therapy, Humira’s effect on individual patients, and InterMune’s Esbriet, a therapy for idiopathic pulmonary fibrosis.
AbbVie is the U.S. pharmaceutical company recently spun off from Abbott Laboratories
In a statement provided to Bloomberg, AbbVie said that it is “seeking to protect AbbVie’s confidential and commercially-sensitive information.”
http://www.burrillreport.com/article-drug_companies_sue_ema_over_trials_data.html
“We consider this information to be commercially confidential.”
The lawsuits, first reported in the Financial Times, seek injunctions to prevent the release of detailed information about AbbVie’s rheumatoid arthritis therapy, Humira’s effect on individual patients, and InterMune’s Esbriet, a therapy for idiopathic pulmonary fibrosis.
AbbVie is the U.S. pharmaceutical company recently spun off from Abbott Laboratories
In a statement provided to Bloomberg, AbbVie said that it is “seeking to protect AbbVie’s confidential and commercially-sensitive information.”
http://www.burrillreport.com/article-drug_companies_sue_ema_over_trials_data.html
No comments:
Post a Comment